Trigeminal neuralgia: a systematic review

Detalhes bibliográficos
Autor(a) principal: Lima, Bruno José Santos
Data de Publicação: 2021
Outros Autores: Sandes, Maylla Fontes, Pereira, Débora Silva, Lima, Angela Santos, Oliveira, Catharina Garcia de, Lopes, Gabriel Dantas, Freitas, Ana Isabel Machado de, Santos, Fernanda Bastos, Andrade, Mariana Alma Rocha de, Melo, Leonardo Santos
Tipo de documento: Artigo
Idioma: por
Título da fonte: Scire Salutis
Texto Completo: https://sustenere.inf.br/index.php/sciresalutis/article/view/5698
Resumo: Paroxysmal attacks of excruciating pain characterize trigeminal neuralgia, a clinical manifestation of an affection of the maxillary branch. It is considered one of the most severe and unbearable pains described by medicine, and can even lead to suicide. There is great difficulty in carrying out controlled therapeutic work on trigeminal neuralgia, as the cases are infrequent and it is unacceptable not to treat the patient in a placebo group. For this reason, the work in question aims to carry out a systematic review of the reports and descriptions existing in scientific journals. The present study consisted of a systematic review of the literature, with synthesis and analysis of clinical findings and meta-analysis of the quantitative data available in articles from indexed journals, both in Brazil and in other countries. Trigeminal neuralgia is a condition with pathophysiological mechanisms not fully understood. Drug therapy is considered the first-line treatment for NT. The anticonvulsant carbamazepine has been used since 1960 for its effectiveness in approximately 60% to 80% of patients.
id ESS-1_f60c51c2494adf04012fa2251aa3c29f
oai_identifier_str oai:ojs.pkp.sfu.ca:article/5698
network_acronym_str ESS-1
network_name_str Scire Salutis
repository_id_str
spelling Trigeminal neuralgia: a systematic reviewNeuralgia do Trigêmeo: uma revisão sistemáticaAnatomiaNeuralgia do trigêmeoTratamentoAnatomyTrigeminal neuralgiaTreatmentParoxysmal attacks of excruciating pain characterize trigeminal neuralgia, a clinical manifestation of an affection of the maxillary branch. It is considered one of the most severe and unbearable pains described by medicine, and can even lead to suicide. There is great difficulty in carrying out controlled therapeutic work on trigeminal neuralgia, as the cases are infrequent and it is unacceptable not to treat the patient in a placebo group. For this reason, the work in question aims to carry out a systematic review of the reports and descriptions existing in scientific journals. The present study consisted of a systematic review of the literature, with synthesis and analysis of clinical findings and meta-analysis of the quantitative data available in articles from indexed journals, both in Brazil and in other countries. Trigeminal neuralgia is a condition with pathophysiological mechanisms not fully understood. Drug therapy is considered the first-line treatment for NT. The anticonvulsant carbamazepine has been used since 1960 for its effectiveness in approximately 60% to 80% of patients.Os ataques paroxísticos de dor lancinante caracterizam a neuralgia do trigêmeo, uma manifestação clínica de uma afecção do ramo maxilar. É considerada uma das dores mais graves e insuportáveis descritas pela medicina, podendo, inclusive, levar ao suicídio. Há grande dificuldade em se realizarem trabalhos terapêuticos controlados na neuralgia do trigêmeo, pois os casos são infrequentes e é inaceitável não tratar o paciente de um grupo-placebo. Por isso, o trabalho em questão objetiva realizar uma revisão sistemática sobre os relatos e descrições existentes nas revistas científicas. O presente estudo consistiu em uma revisão sistemática da literatura, com síntese e análise dos achados clínicos e meta-análise sobre os dados quantitativos disponíveis em artigos de periódicos indexados, tanto do Brasil como de outros países. A neuralgia trigeminal é uma afecção com mecanismos fisiopatológicos não inteiramente esclarecidos. A terapia medicamentosa é considerada o tratamento de primeira linha para a NT. O anticonvulsivante carbamazepina tem sido usado desde 1960 por sua eficácia em aproximadamente 60% a 80% dos pacientes.Sustenere Publishing2021-06-22info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://sustenere.inf.br/index.php/sciresalutis/article/view/569810.6008/CBPC2236-9600.2021.003.0018Scire Salutis; Vol. 11 No. 3 (2021): Scire Salutis - Jun, Jul, Ago, Set 2021; 136-141Scire Salutis; Vol. 11 Núm. 3 (2021): Scire Salutis - Jun, Jul, Ago, Set 2021; 136-141Scire Salutis; v. 11 n. 3 (2021): Scire Salutis - Jun, Jul, Ago, Set 2021; 136-1412236-9600reponame:Scire Salutisinstname:Companhia Brasileira de Produção Científica (CBPC)instacron:ESSporhttps://sustenere.inf.br/index.php/sciresalutis/article/view/5698/3058Copyright (c) 2021 Scire Salutishttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccess Lima, Bruno José SantosSandes, Maylla Fontes Pereira, Débora SilvaLima, Angela Santos Oliveira, Catharina Garcia deLopes, Gabriel Dantas Freitas, Ana Isabel Machado de Santos, Fernanda Bastos Andrade, Mariana Alma Rocha deMelo, Leonardo Santos2023-01-04T20:16:52Zoai:ojs.pkp.sfu.ca:article/5698Revistahttps://sustenere.co/index.php/sciresalutisONGhttps://sustenere.co/index.php/sciresalutis/oai||carlos@arvore.org.br2236-96002236-9600opendoar:2023-01-04T20:16:52Scire Salutis - Companhia Brasileira de Produção Científica (CBPC)false
dc.title.none.fl_str_mv Trigeminal neuralgia: a systematic review
Neuralgia do Trigêmeo: uma revisão sistemática
title Trigeminal neuralgia: a systematic review
spellingShingle Trigeminal neuralgia: a systematic review
Lima, Bruno José Santos
Anatomia
Neuralgia do trigêmeo
Tratamento
Anatomy
Trigeminal neuralgia
Treatment
title_short Trigeminal neuralgia: a systematic review
title_full Trigeminal neuralgia: a systematic review
title_fullStr Trigeminal neuralgia: a systematic review
title_full_unstemmed Trigeminal neuralgia: a systematic review
title_sort Trigeminal neuralgia: a systematic review
author Lima, Bruno José Santos
author_facet Lima, Bruno José Santos
Sandes, Maylla Fontes
Pereira, Débora Silva
Lima, Angela Santos
Oliveira, Catharina Garcia de
Lopes, Gabriel Dantas
Freitas, Ana Isabel Machado de
Santos, Fernanda Bastos
Andrade, Mariana Alma Rocha de
Melo, Leonardo Santos
author_role author
author2 Sandes, Maylla Fontes
Pereira, Débora Silva
Lima, Angela Santos
Oliveira, Catharina Garcia de
Lopes, Gabriel Dantas
Freitas, Ana Isabel Machado de
Santos, Fernanda Bastos
Andrade, Mariana Alma Rocha de
Melo, Leonardo Santos
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Lima, Bruno José Santos
Sandes, Maylla Fontes
Pereira, Débora Silva
Lima, Angela Santos
Oliveira, Catharina Garcia de
Lopes, Gabriel Dantas
Freitas, Ana Isabel Machado de
Santos, Fernanda Bastos
Andrade, Mariana Alma Rocha de
Melo, Leonardo Santos
dc.subject.por.fl_str_mv Anatomia
Neuralgia do trigêmeo
Tratamento
Anatomy
Trigeminal neuralgia
Treatment
topic Anatomia
Neuralgia do trigêmeo
Tratamento
Anatomy
Trigeminal neuralgia
Treatment
description Paroxysmal attacks of excruciating pain characterize trigeminal neuralgia, a clinical manifestation of an affection of the maxillary branch. It is considered one of the most severe and unbearable pains described by medicine, and can even lead to suicide. There is great difficulty in carrying out controlled therapeutic work on trigeminal neuralgia, as the cases are infrequent and it is unacceptable not to treat the patient in a placebo group. For this reason, the work in question aims to carry out a systematic review of the reports and descriptions existing in scientific journals. The present study consisted of a systematic review of the literature, with synthesis and analysis of clinical findings and meta-analysis of the quantitative data available in articles from indexed journals, both in Brazil and in other countries. Trigeminal neuralgia is a condition with pathophysiological mechanisms not fully understood. Drug therapy is considered the first-line treatment for NT. The anticonvulsant carbamazepine has been used since 1960 for its effectiveness in approximately 60% to 80% of patients.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-22
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://sustenere.inf.br/index.php/sciresalutis/article/view/5698
10.6008/CBPC2236-9600.2021.003.0018
url https://sustenere.inf.br/index.php/sciresalutis/article/view/5698
identifier_str_mv 10.6008/CBPC2236-9600.2021.003.0018
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://sustenere.inf.br/index.php/sciresalutis/article/view/5698/3058
dc.rights.driver.fl_str_mv Copyright (c) 2021 Scire Salutis
http://creativecommons.org/licenses/by-nc-nd/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Scire Salutis
http://creativecommons.org/licenses/by-nc-nd/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sustenere Publishing
publisher.none.fl_str_mv Sustenere Publishing
dc.source.none.fl_str_mv Scire Salutis; Vol. 11 No. 3 (2021): Scire Salutis - Jun, Jul, Ago, Set 2021; 136-141
Scire Salutis; Vol. 11 Núm. 3 (2021): Scire Salutis - Jun, Jul, Ago, Set 2021; 136-141
Scire Salutis; v. 11 n. 3 (2021): Scire Salutis - Jun, Jul, Ago, Set 2021; 136-141
2236-9600
reponame:Scire Salutis
instname:Companhia Brasileira de Produção Científica (CBPC)
instacron:ESS
instname_str Companhia Brasileira de Produção Científica (CBPC)
instacron_str ESS
institution ESS
reponame_str Scire Salutis
collection Scire Salutis
repository.name.fl_str_mv Scire Salutis - Companhia Brasileira de Produção Científica (CBPC)
repository.mail.fl_str_mv ||carlos@arvore.org.br
_version_ 1793890278342393856

Registros relacionados